Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Clinical Trials

Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers

Phase 1

Conditions: Healthy

Interventions: Drug: prasugrel

First Posted Date: 2014-03-03

Last Posted Date: 2014-03-04

Lead Sponsor: Asan Medical Center

Target Recruit Count: 8

Registration Number: NCT02075268

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Phase 3

Terminated

Conditions: ST-Segment Elevation Myocardial Infarction

Interventions: Drug: Ticagrelor 180 mg
Drug: Prasugrel 60 mg

First Posted Date: 2014-03-03

Last Posted Date: 2017-08-18

Lead Sponsor: Dong-A University

Target Recruit Count: 39

Registration Number: NCT02075125

Locations: 🇰🇷
DongA University Hospital, Busan, Korea, Republic of

Prasugrel With Lower Dose - Loading Dose

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel 60 mg
Drug: Clopidogrel 600 mg
Drug: Prasugrel 30 mg

First Posted Date: 2014-02-25

Last Posted Date: 2014-02-25

Lead Sponsor: Dong-A University

Target Recruit Count: 43

Registration Number: NCT02070159

Locations: 🇰🇷
DongA University Hospital, Busan, Korea, Republic of

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2014-02-19

Last Posted Date: 2020-09-16

Lead Sponsor: University of Florida

Target Recruit Count: 65

Registration Number: NCT02065479

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .

Phase 4

Conditions: Acute Coronary Syndrome
Non ST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Unstable Angina

Interventions: Procedure: Assessment of coronary flow reserve
Procedure: Percutaneous Coronary Intervention
Drug: Ticagrelor loading
Drug: Prasugrel loading

First Posted Date: 2014-01-10

Last Posted Date: 2014-01-10

Lead Sponsor: Azienda Policlinico Umberto I

Target Recruit Count: 88

Registration Number: NCT02032303

Locations: 🇮🇹
Massimo Mancone, Rome, Italy

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

Not Applicable

Completed

Conditions: Acute Coronary Syndrome
Coronary Artery Disease

Interventions: Drug: Prasugrel 10mg
Drug: Ticagrelor 180mg
Drug: Ticagrelor 90mg

First Posted Date: 2013-12-19

Last Posted Date: 2024-07-03

Lead Sponsor: University of Florida

Target Recruit Count: 82

Registration Number: NCT02016170

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Cangrelor to Clopidogrel or Prasugrel Transition Study

Phase 2

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Cangrelor
Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-11-08

Last Posted Date: 2020-02-26

Lead Sponsor: The Medicines Company

Target Recruit Count: 15

Registration Number: NCT01979445

Locations: 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-10-10

Last Posted Date: 2019-03-01

Lead Sponsor: LMU Klinikum

Target Recruit Count: 2600

Registration Number: NCT01959451

Locations: 🇦🇹
Wilhelminenspital Wien, 3. Medizinische Abteilung, Vienna, Austria
🇦🇹
Medizin-Universität Graz, Univ. Klinik für Innere Medizin, Graz, Austria
🇭🇺
Heart Center Szeged, Szeged, Hungary

and more 30 locations